anti cd47 antibody  (Bio X Cell)

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: PD-1/IL-2 bsAb protects CD8 + T cells from macrophage phagocytosis via STAT5-mediated upregulation of CD47 (A) Schematic of the Cleavage Under Targets and Tagmentation (CUT&Tag) assays workflow. (B) Distribution of STAT5 binding signals relative to transcription start sites (TSS) in CD8 + T cells treated with or without the PD-1/IL-2 bsAb. (C) Genomic annotation of differentially enriched STAT5 binding peaks in the bsAb-treated group. (D) KEGG pathway enrichment analysis of genes associated with STAT5 binding peaks. (E and F) Strategy and Venn diagram for identifying potential STAT5 downstream genes. (G) ChIP-qPCR analysis of STAT5 binding to the promoter regions of selected candidate genes ( n = 3). (H) Genome browser tracks showing STAT5 binding signals at the CD47 locus in control and PD-1/IL-2 bsAb-treated CD8 + T cells. (I) Schematic of the macrophage phagocytosis assay. (J) Representative confocal microscopy images showing macrophages (red) engulfing CD8 + T cells (green). Scale bars, 20 μm. (K) Flow cytometry quantification of the percentage of macrophages that had phagocytosed CD8 + T cells under the indicated conditions ( n = 3). Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: CD47 Polyclonal Ab , Proteintech , Cat#20305-1-AP; RRID: AB_10732838.

Techniques: Binding Assay, ChIP-qPCR, Control, Phagocytosis Assay, Confocal Microscopy, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: CD47 protects CD8 + T cells from macrophage clearance to boost antitumor immunity in SMARCA4-deficient NSCLC (A) Schematic of the adoptive T cell therapy experiment ( n = 8/group). (B) Representative in vivo bioluminescence images of mice from the indicated treatment groups at different time points. (C) Tumor growth curves, as measured by bioluminescence, for mice in each treatment group. (D) Individual tumor growth curves for mice in each treatment group. (E) Kaplan-Meier survival curves of mice from the four treatment groups. (F) Quantification by flow cytometry of donor-derived CD45.2 + CD8 + T cells among total tumor-infiltrating lymphocytes. (G) Representative flow cytometry plots for donor-derived CD45.2 + CD8 + T cells expressing the exhaustion markers PD-1, TIGIT, and TIM-3. (H) Quantification of the percentage of CD45.2 + CD8 + T cells expressing PD-1, TIGIT, and TIM-3. (I) The production of TNF-α by donor-derived CD45.2 + CD8 + T cells. (J) The production of IFN-γ by donor-derived CD45.2 + CD8 + T cells. (K) Representative immunofluorescence images of tumor sections. White: CD8, green: CD47, red: F4/80. Scale bars, 70 μm. (L) Schematic model depicting the proposed mechanism of action. Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by one-way ANOVA.

Article Snippet: CD47 Polyclonal Ab , Proteintech , Cat#20305-1-AP; RRID: AB_10732838.

Techniques: In Vivo, Flow Cytometry, Derivative Assay, Expressing, Immunofluorescence

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: MYC promotes the progression of prostate cancer by regulating CD47 to induce an immunosuppressive microenvironment

doi: 10.1007/s00018-026-06109-0

Figure Lengend Snippet: MYC promotes M2 macrophage differentiation by regulating CD47 expression. A Immunofluorescence showed the intercellular localization of MYC and CD47. B-C After knocking down MYC, MYC and CD47 protein and mRNA levels in the cells changed. D The JASPAR database predicted potential MYC-binding sites on the CD47 promoters. E MYC binding to the CD47 promoter was evaluated by ChIP-qPCR assay. F Process of cell co-culture. G Expression levels of the marker gene in M1 and M2 macrophages. H The interaction between SIRPα and CD47 was validated by the Co-IP assay. I-J Differential genes and gene enrichment results were shown. K-L Western blot results showed changes in PI3K/AKT protein expression levels. M Expression levels of the marker gene in M1 and M2 macrophages

Article Snippet: Finally, the sections were counterstained with DAPI for 10 min, washed, and mounted with an anti-fade mounting medium. (Myc: Abcam, ab32072; CD47: Proteintech, 20305-1-AP; CD206: Cell Signaling Technology, 24595 T; CD8: Abcam, ab237709).

Techniques: Expressing, Immunofluorescence, Binding Assay, ChIP-qPCR, Co-Culture Assay, Marker, Co-Immunoprecipitation Assay, Western Blot

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: MYC promotes the progression of prostate cancer by regulating CD47 to induce an immunosuppressive microenvironment

doi: 10.1007/s00018-026-06109-0

Figure Lengend Snippet: The role of macrophages in modulating the functional behaviors of PCa cells. A Cells were co-cultured for display. B-C The proportion of CD8 + T cells was measured by flow cytometry. D Transwell assay results showed the effect of MYC and CD47 expression on the invasion ability of PCa cells. E. EdU assay results showed the effect of MYC and CD47 expression levels on the proliferation of PCa cells. F-G The results of the colony-formation and wound-healing experiments showed the effects of MYC and CD47 expression levels on the proliferation and migration of PCa cells. H Representative multiplex immunofluorescence staining images depict MYC, CD47, CD8 + T and M2 cell in PCa tissues

Article Snippet: Finally, the sections were counterstained with DAPI for 10 min, washed, and mounted with an anti-fade mounting medium. (Myc: Abcam, ab32072; CD47: Proteintech, 20305-1-AP; CD206: Cell Signaling Technology, 24595 T; CD8: Abcam, ab237709).

Techniques: Functional Assay, Cell Culture, Flow Cytometry, Transwell Assay, Expressing, EdU Assay, Migration, Multiplex Assay, Immunofluorescence, Staining